HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer

Recently, it was described that an HLA-A24 restricted peptide derived from the survivin splice variant survivin-2B can be recognized by CD8(+) cytotoxic T-cells. The identification of an HLA-A24 epitope is critical for survivin-based immunotherapy as HLA-24 is the most frequent HLA allele in Asia. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersen, Mads Hald, Soerensen, Rikke B, Becker, Jürgen C, thor Straten, Per
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564416/
https://www.ncbi.nlm.nih.gov/pubmed/16948867
http://dx.doi.org/10.1186/1479-5876-4-38

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564416/
https://www.ncbi.nlm.nih.gov/pubmed/16948867
http://dx.doi.org/10.1186/1479-5876-4-38

Ejemplares similares